Revenue and Profit Growth - Revenue for the third quarter reached 700,065,714.12 yuan, a year-on-year increase of 47.74%[2] - Net profit attributable to shareholders of the listed company was 239,128,282.41 yuan, up 63.62% compared to the same period last year[2] - Revenue increased by 47.76% to 2,195,690,243.92 yuan, driven by rapid growth in sales of perfusion and adsorption products[7] - Net profit surged by 87.63% to 788,826,841.30 yuan, primarily due to increased sales revenue and a decrease in period expense ratio[8] - Operating revenue for the period reached 2,195,690,243.92 yuan, compared to 1,485,982,086.00 yuan in the same period last year[22] - Net profit attributable to the parent company's owners rose to 2,485,766,350.81 yuan, up from 2,003,918,783.75 yuan at the beginning of the period[21] - Net profit attributable to parent company shareholders reached RMB 791.63 million, a significant increase from RMB 423.66 million in the same period last year[23] - The company's total comprehensive income for the period was RMB 788.83 million, up from RMB 420.44 million in the previous year[24] Asset and Liability Changes - Total assets as of the end of the reporting period were 5,593,125,792.01 yuan, an increase of 0.90% from the end of the previous year[2] - Total assets increased to 5,593,125,792.01 yuan, up from 5,543,301,641.00 yuan at the beginning of the period[21] - Total liabilities decreased to 2,299,898,618.97 yuan, down from 2,390,427,115.63 yuan at the beginning of the period[20] - Total equity attributable to the parent company's owners increased to 3,289,267,081.77 yuan, up from 3,147,475,025.76 yuan at the beginning of the period[21] Cash Flow and Financial Activities - Cash flow from operating activities increased by 47.72% to 871,604,805.56 yuan, driven by higher sales revenue and improved collection[9] - Investment activities resulted in a net cash outflow of 2,177,751,665.93 yuan, mainly due to the purchase of financial products[10] - Financing activities led to a net cash outflow of 727,689,551.18 yuan, primarily due to reduced bank borrowings and increased share repurchase payments[10] - Cash flow from operating activities increased to RMB 871.60 million, up from RMB 590.04 million in the prior year[26] - Investment activities resulted in a net cash outflow of RMB 2.18 billion, primarily due to investment payments of RMB 3.57 billion[26][27] - Financing activities generated a net cash outflow of RMB 727.69 million, with debt repayments totaling RMB 364.16 million[27] Financial Position and Cash Equivalents - The company's monetary funds decreased by 74.35% to 720,879,803.21 yuan, mainly due to the purchase of financial products and payment of share repurchases and dividends[5] - Cash and cash equivalents decreased by 73.71% to 706,919,138.82 yuan, mainly due to the purchase of financial products and share repurchase payments[10] - Cash and cash equivalents stood at 720,879,803.21 yuan, a significant drop from 2,810,294,219.25 yuan at the beginning of the period[18] - The company's cash and cash equivalents at the end of the period stood at RMB 706.92 million, a decrease from RMB 2.69 billion at the beginning of the period[27] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 47,817[11] - Dong Fan holds 44.47% of the shares, totaling 355,131,867 shares[11] - Tang Xianmin holds 2.67% of the shares, totaling 21,336,425 shares[11] - China Bank Co., Ltd. - Huabao CSI Medical ETF holds 2.04% of the shares, totaling 16,261,281 shares[11] - Hong Kong Securities Clearing Company Ltd. holds 1.59% of the shares, totaling 12,689,098 shares[11] - Industrial and Commercial Bank of China Co., Ltd. - E Fund ChiNext ETF holds 1.50% of the shares, totaling 11,998,489 shares[11] - Agricultural Bank of China Co., Ltd. - CSI 500 ETF holds 1.12% of the shares, totaling 8,958,300 shares[11] - Guo Xuerui holds 1.01% of the shares, totaling 8,040,792 shares[11] - Jiang Huanxin holds 1.00% of the shares, totaling 8,000,882 shares[11] - China Bank Co., Ltd. - China Merchants Guozheng Biopharmaceutical Index Fund holds 0.98% of the shares, totaling 7,791,386 shares[11] Expenses and Costs - Operating costs rose by 42.80% to 410,333,473.21 yuan due to increased sales of perfusion and adsorption products[7] - Financial expenses surged by 185.67% to 49,843,991.71 yuan due to a decrease in deposit ratio and increased interest expenses on convertible bonds[7] - Income tax expenses increased by 111.33% to 165,792,667.72 yuan, driven by higher sales revenue and profits[8] - Research and development expenses amounted to 174,715,744.33 yuan, slightly down from 176,357,010.23 yuan in the same period last year[22] - Interest expenses increased to RMB 47.95 million, up from RMB 40.29 million in the previous year[23] Other Financial Metrics - Transactional financial assets increased to 1,993,010,954.97 yuan, primarily due to the purchase of financial products[5] - Accounts receivable financing surged by 1576.55% to 106,616,453.05 yuan, driven by an increase in bank acceptance bills held at the end of the period[5] - Prepayments rose by 143.63% to 28,189,361.94 yuan, mainly due to increased prepayments for raw material purchases[5] - Construction in progress increased by 52.72% to 186,975,903.32 yuan, reflecting higher investments in production equipment and factory construction[5] - Taxes payable surged by 119.17% to 125,821,283.55 yuan, driven by growth in sales revenue and profits[6] - Long-term loans decreased by 31.70% to 276,565,114.40 yuan, partly due to early repayment of some bank loans and reclassification of maturing loans[6] - Government subsidies increased by 49.84% to 52,078,282.13 yuan compared to the same period last year[7] - Trade receivables increased to 92,523,595.64 yuan, up from 74,850,201.41 yuan at the beginning of the period[18] - Inventory decreased to 312,560,202.84 yuan, down from 384,996,423.31 yuan at the beginning of the period[18] - Fixed assets stood at 1,617,425,679.54 yuan, down from 1,633,717,142.19 yuan at the beginning of the period[19] - Basic earnings per share (EPS) for the current period was RMB 0.99, compared to RMB 0.53 in the previous year[24] - Sales revenue from goods and services provided reached RMB 2.31 billion, a rise from RMB 1.78 billion in the previous year[25] - Other income rose to RMB 52.08 million, compared to RMB 34.76 million in the same period last year[23] - The company's third quarter report was not audited[28]

证券代码：300529 证券简称：健帆生物 公告编号：2024-080 债券代码：123117 债券简称：健帆转债 1 1、 健帆转债（债券代码：123117）的转股期限为 2021 年 12 月 29 日至 2027 年 6 月 22 日，最新有效的转股价格为 39.43 元/股。 2、 2024 年第三季度，"健帆转债"未发生转股情况。 3、 截至 2024 年第三季度末，公司剩余可转换公司债券为 9,998,423 张，剩 余票面金额 999,842,300 元人民币。 健帆生物科技集团股份有限公司 关于 2024 年第三季度健帆转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》等有关规定，健帆生物科技集团股份 有限公司（以下简称"公司"）现将 2024 年第三季度可转换公司债券（以下简 称"健帆转债"）转股及公司股本变化情况公告如下： 一、可转换公司债券发行上市情况 （一）可转换公司债券发行情况 经中国证券监督管理 ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-079 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2024 年 7 月 16 日 召开了 2024 年第二次临时股东大会，审议通过了《关于注销部分回购股份、减 少注册资本暨修订<公司章程>的议案》，鉴于公司注销回购专用证券账户中的 884.6037 万股股票，使得公司总股本相应减少 884.6037 万股，公司总股本从 80745.1312 万股减少至 79860.5275 万股，公司注册资本由 80745.1312 万元减少 至 79860.5275 万元。 2、核准变更登记通知书。 特此公告。 健帆生物科技集团股份有限公司董事会 8、经营范围：许可项目：第三类医疗器械生产；第三类医疗器械经营；第 三类医疗器械租赁；第二类医疗器械生产；食品销售；第二类增值电信业务；医 疗器械互联网信息服务；药品互联网信息服务；药品批发；药品零售；药品进出 ...

| 证券代码：300529 | 证券简称：健帆生物 公告编号：2024-078 | | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | 健帆生物科技集团股份有限公司 关于奋斗者二号员工持股计划锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 6 月 2 日召开第五届董事会第三次会议、第五届监事会第三次会议，于 2023 年 6 月 19 日召开 2023 年第一次临时股东大会，审议通过了《关于公司<奋斗者二号员 工持股计划（草案）>及其摘要的议案》《关于公司<奋斗者二号员工持股计划管 理办法>的议案》《关于提请公司股东大会授权董事会办理奋斗者二号员工持股 计 划 相 关 事 宜 的 议 案 》 等 议 案 ， 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 鉴于公司奋斗者二号员工持股计划（以下简称"本员工持股计划"或"持股 计划"） 锁定期已于 2024 年 9 月 17 日 ...

Group 1: Internationalization and Market Penetration - The company's products are currently used in over 2,000 hospitals worldwide, with more than 90 types of HA series blood perfusion devices and BS series bilirubin adsorption devices having obtained EU MDR certification, facilitating promotion and sales in EU countries and other regions recognizing this certification [2] - In the liver disease sector, the company has covered over 2,000 hospitals, while products related to critical care have reached over 1,600 hospitals [3] - The penetration rate of blood perfusion technology in the liver and critical care fields is still in the early stages, indicating significant growth potential [3] Group 2: Product Development and Future Prospects - The pHA series blood perfusion devices, launched in November 2023, are the first globally to effectively adsorb both large molecular toxins and protein-bound toxins in uremic patients, with over 60 hospitals currently promoting their use [3] - The company is committed to increasing R&D investment for new products and has the capability to develop various products for different diseases based on its original blood perfusion technology [3] Group 3: Procurement and Market Strategy - In March 2024, the company participated in the inter-provincial procurement of blood dialysis medical consumables in Henan, securing qualifications for high-flow and non-high-flow blood dialysis devices, as well as blood dialysis tubing products [4] - The company has established a solid foundation for deepening its presence in the blood purification market, with a demand of approximately 900,000 units for its products from around 800 medical institutions [4] Group 4: Financial Performance and Future Outlook - The company is currently operating smoothly, with production capacity meeting business development needs and utilization rates within a reasonable range [5] - There is confidence in returning to a stable growth trajectory, with specific operational details to be disclosed in regular reports [5]

证券代码：300529 证券简称：健帆生物 公告编号：2024-077 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 一、关于健帆转债转股价格调整的相关规定 健帆生物科技集团股份有限公司（以下简称"公司"）于 2021 年 6 月 23 日 向不特定对象发行可转债 1000 万张（债券简称：健帆转债，债券代码：123117）， 根据《健帆生物科技集团股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》（以下简称《募集说明书》）：在本次发行之后，当公司发生派送 股票股利、转增股本、增发新股（不包括因本次发行的可转债转股而增加的股本）、 配股以及派发现金股利等情况时，将按下述公式对转股价格进行调整（保留小数 点后两位，最后一位四舍五入）： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：123117 债券简称：健帆转债 5、本次调整的原因：部分回购股份注销完成，使公司总股本数量发生变动。 派送股票股利或转增股本：P1=P0/（1+n）； 增发新股或配股：P1=（P0+A×k）/（1+k）； 上述两项同 ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-076 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、回购股份的基本情况 公司于 2021 年 8 月 26 日召开第四届董事会第二十五次会议、于 2021 年 9 月 14 日召开 2021 年第三次临时股东大会审议通过了《关于回购公司股份方案的 议案》，同意公司使用自有资金以集中竞价方式回购公司股份，回购金额不低于 人民币 2.5 亿元且不超过人民币 5 亿元，用于未来公司实施员工持股计划、股权 激励或用于转换上市公司发行的可转换为股票的公司债券。 1、本次注销的回购股份数量为 8,846,037 股，占注销前公司总股本的 1.0956%。 本次注销完成后，公司总股本由 807,451,312 股变更为 798,605,275 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购 股份注销事宜已于近日办理完成。 根据《中华人民共和国公司法》《深圳 ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-075 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于参加广东辖区 2024 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，健帆生物科技集团股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"坚定信心 携 手共进 助力上市公司提升投资价值——2024 广东辖区上市公司投资者关系管 理月活动投资者集体接待日"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2024 年 9 月 12 日（星期四） 15:30 ~16:30。 届时公司董事长兼总经理董凡先生、董事兼财务总监廖雪云女士、董事会秘 书黄聪女士将通过网络在线方式，与投资者就公司治理、经营情况及发展战略等 投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者积极参与。 特此公告。 健帆生物科技集团股份有限 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2024-073 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 关于公司产品获得欧盟 MDR 认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于近日收到欧盟公告机 构通知，公司产品细胞因子吸附柱（CA）（以下简称"CA 产品"）和一次性使用 血液灌流器（KHA）（以下简称"KHA 产品"）获得按照欧盟医疗器械法规 Medical Devices Regulation（EU）2017/745（以下简称"MDR"）签发的欧盟 MDR 认证， 可在欧盟国家及其他认可欧盟 CE 认证国家销售。现将相关情况公告如下： 一、MDR 认证证书主要内容 二、医疗器械基本情况 上述产品的市场销售可能会受到欧盟法规政策、市场环境变化、以及汇率波 动等不确定因素的影响，公司尚无法预测其对公司未来业绩的具体影响。敬请广 大投资者谨慎投资、注意投资风险。 特此公告。 健帆生物 ...